

Wegovy[®] (semaglutide) – Updated dosing

- On July 21, 2023, the <u>FDA approved</u> an update to the drug label for <u>Wegovy (semaglutide)</u> to include 1.7 mg subcutaneous weekly as an additional maintenance dose for use as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition.
 - Previously, Wegovy was only approved with a maintenance dose of 2.4 mg once weekly.
- In adults, Wegovy is initiated at a dosage of 0.25 mg injected subcutaneously (SC) once-weekly. The updated dose escalation schedule is presented in the table below.

Treatment	Weeks	Once weekly SC dosage
Initiation	1 through 4	0.25 mg
Escalation	5 through 8	0.5 mg
	9 through 12	1 mg
	13 through 16	1.7 mg
Maintenance	17 and onward	1.7 mg or 2.4 mg

- Wegovy is also approved in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater standardized for age and sex (obesity).
 - The maintenance dosage of Wegovy in pediatric patients aged 12 years and older is 2.4 mg weekly.
- Wegovy carries a boxed warning for risk of thyroid C-cell tumors.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.